Think slow drug development = safe? Wrong. Australia approves low-risk trials in weeks. COVID proved remote trials work. China's biotech now dominates 1/3 of pharma acquisitions—not better science, just faster regulation. Time to fix U.S. inefficiencies.

Thrilled to welcome David Saunders, MD, MPH to our clinical development team! A distinguished U.S. Army Colonel & clinical trialist, his expertise in infectious disease research will be crucial as we advance LMN-201 and our oral biologics pipeline. https://t.co/TOqIBsaJlO

Proud to announce Kole Krieger's promotion to Senior Vice President! His leadership in partnerships and operational excellence is crucial as we prepare for LMN-201's launch and advance our oral biologics pipeline. https://t.co/TOqIBsaJlO

Congratulations to Nhi Khuong, PhD on her promotion to Executive Vice President! Her scientific leadership has been crucial in advancing our biologics platform through clinical development as we prepare for LMN-201's launch. https://t.co/TOqIBsabwg

Welcoming @jeffraikes to our board! His leadership experience at @Microsoft, @gatesfoundation & @Costco will be invaluable as we scale our biologics platform globally. https://t.co/TOqIBsaJlO

Excited to announce Erik Anderson as Vice Chairman of our Board. As CEO of @WestRiverVC & @singularityu, Erik led our Series C and brings invaluable experience as we scale our spirulina-based biologics platform. https://t.co/TOqIBsaJlO

.@_rossry doesn't ask easy questions—he asks the right ones. Honored to be an early guest on the new @DevAndResearch interview series, where we dug deep on what makes drug development tick.

Good or bad, when institutions are remade it's an opportunity for fresh new ideas to root. There's plenty of negative criticism out there—from all sides—but @innovationwonk and I jotted down some constructive ideas to throw into the mix—published here in @statnews

https://t.co/0yp2bVO442

Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). https://t.co/u0UZJWFJcP #PatientCare #Clinicaltrial

Breaking through intranasal biologics production barriers. Our CEO Brian Finrow presents "Keep It Simple Stupid" at the @HansonWade Nasal Formulation Summit in Boston next week. Register: https://t.co/ITy8Ibzyvt April 1-3, 2024 | Boston, MA

Join us next Tuesday as our CEO Brian Finrow moderates Life Science Washington's expert panel on moving new drugs into the clinic. March 25, 2025 | 11:30 AM - 1:30 PM | Seattle, WA Register through @LifeScienceWA: https://t.co/n9d9gWOAvL

We're recruiting now for RePreve Clinical Trial to prove it! If you know someone who'd benefit, please send them our way! https://t.co/Cudeo1YcLA cc'ing @PeggyFund

(To be clear, we aim for superior efficacy too—stay tuned for some upcoming news on that. 🤞)

Efficacy is important, but not dispositive in recurrence markets. Zinplava had it (~33% recurrence prevention) but it did not save them because it struggled on these other fronts.

Seems obvious. From what's shared publicly, it lacked 3 key attributes of Lumen's LMN-201: (1) low COGS, (2) safety, (3) convenience (LMN-201 is oral capsules; no IV, enema, or 'bowel cleanse' required).

Full article here: https://t.co/rbG7FbmGIt Zinplava had decent efficacy (~33%), but Merck just withdrew it from the market. Why?

New piece by me here in Medical Economics (link in replies). Simple premise: in economics terms, #Cdiff is a scourge; prevention beats treating after symptoms are raging. Prevention is more socially valuable. But if that's true, why did Merck just yank Zinplava from the market?

I wish I were as good as @brianbuntz at distilling complex science into a simple story. The piece he published yesterday on our LMN-201 product captures the full story in just 750 words, including a fair amount of technical detail. Impressive!

This was tons of fun. IMO, @mattpillar is the best podcast host in biotech. https://t.co/9F3quTs1o6